BioSpace News Archive

Globus Medical, Inc. announced the commercial launch of the MARVEL™ Growing Rod System, which is designed for pediatric patients with early onset scoliosis to obtain and maintain correction while allowing for growth through minimally invasive distraction.

PharmAla Biotech Holdings Inc. is thrilled that it has filed a patent on the composition of matter of PharmAla-1.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, August 1, 2023, at 8:30 AM ET to discuss results for the second quarter 2023 and provide a business outlook for remainder of the year.

T2 Biosystems, Inc. announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension through November 20, 2023, to evidence compliance with Nasdaq’s minimum bid price and market value of listed securities (“MVLS”) requirements.

RenovoRx, Inc today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, August 3, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended June 30, 2023.

OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) and options (“Options”) to a new employee, Michael Louie, SVP Medical Affairs & Clinical Development, in connection with his commencing employment with UroGen.

COMPASS Pathways plc, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it will release financial results for the second quarter 2023, and provide an update on recent business developments on August 3, 2023.

Sera Prognostics Inc. today announced that it will report second quarter fiscal year 2023 financial results on Wednesday, August 9, 2023, after the close of the market.